trending Market Intelligence /marketintelligence/en/news-insights/trending/MeA2htChfQ4Ol1r3ERyCwg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eagle resubmits US FDA application for Ryanodex to treat exertional heatstroke

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eagle resubmits US FDA application for Ryanodex to treat exertional heatstroke

Eagle Pharmaceuticals Inc. resubmitted a new drug application with the U.S. Food and Drug Administration seeking approval of Ryanodex to treat exertional heatstroke.

The agency is expected to give its decision six months from the submission, Eagle Pharmaceuticals said in a Jan. 9 press release.

The U.S. regulator rejected an earlier application for Ryanodex to treat exertional heatstroke, which is characterized by elevated core body temperature and can trigger sudden behavioral changes, seizures or coma. Headache and hyperthermia are the key initial symptoms of exertional heatstroke.

The Woodcliff Lake, N.J.-based biotechnology company, which develops injectable products in critical care and cancer treatment in the U.S., was asked in July 2017 by the FDA to conduct an additional clinical trial to evaluate Ryanodex for the same indication.

Ryanodex was recently granted orphan-drug designation by the U.S. regulator for its potential treatment of organophosphate exposure. Organophosphates are chemical substances used in potent pesticides and chemical weapons known as nerve agents. According to the U.S. Centers for Disease Control and Prevention, organophosphates are the most widely used insecticides today. Acute intoxication with organophosphates could lead to brain damage and death.

The drug is already approved for treating malignant hyperthermia in conjunction with appropriate supportive measures and for malignant hyperthermia in patients at high risk.